JPRN-UMIN000010228已完成2 期
eoadjuvant chemotherapy with Paclitaxel/Bevacizumab followed by FEC (5-Fluorouracil/Epirubicin/Cyclophosphamide) for triple negative operable primary breast cancer - Neoadjuvant Paclitaxel/Bevacizumab followed by FEC therapy for triple negative breast cancer
Department of Surgery, Division of Breast and Endocrine Surgery, St. Marianna University School of Medicine0 个研究点目标入组 20 人开始时间: 2013年3月13日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) drug allergy 2) severe complications (malignant hypertension, congestive heart failure, coronary heart disease, myocardial infarction (onset within 6 months), arrhythmia (treated), infectious disease, bleeding tendency, etc) 3) feber, infection 4) peripheral neuropathy 5) pleural effusion, pericardial effusion 6) active double cancer 7) inflammatory breast cancer 8) male breast cancer 9) pregnancy 10) severe edema 11) interstitial pneumonia, fibrous lung disease 12) steroid-using patients 13) psychosomatic disease 14) active digestive ulcer 15) unsuitable patients
研究者
相似试验
已完成
2 期
A phase II study of additional chemotherapy (neoadjuvant) followed by standard chemoradiation for locally advanced cervical carcinomaCTRI/2012/07/002758Dr BR Ambedkar Institute Rotary Cancer Hospital20
招募中
2 期
eoadjuvant Chemotherapy with Cabazitaxel on patients with high risk Prostate Cancer prior to Radical ProstatectomyC61Malignant neoplasm of prostateDRKS00005269Sanof Aventis Group, Paris35
招募中
2 期
Paclitaxel plus cisplatin as adjuvant chemotherapy for advanced cervical cancerJPRN-jRCTs051180220Sumi Toshiyuki125
进行中（未招募）
1 期
Preoperative chemotherapy with paclitaxel in women with HER2-negative high-risk breast cancerEUCTR2012-003481-41-ITFONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E CURA DEI TUMORI632
进行中（未招募）
1 期
Preoperative chemotherapy with paclitaxel in women with HER2-negative high-risk breast cancerEUCTR2012-003481-41-DEFONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E CURA DEI TUMORI632